Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(18 days ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7696159 (Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(5 months from now) |
Market Authorisation Date: 27 February, 1997
Treatment: Works through the induction of interferon and other cytokines
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10238645 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Aug, 2029
(5 years from now) | |
US8598196 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Aug, 2029
(5 years from now) | |
US10238644 | BAUSCH | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(5 years from now) | |
US8299109 | BAUSCH | Method of treating actinic keratosis with 3.75% imiquimod cream |
Dec, 2029
(5 years from now) | |
US8236816 | BAUSCH | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
Dec, 2029
(5 years from now) | |
US8222270 | BAUSCH | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
Dec, 2029
(5 years from now) | |
US11318130 | BAUSCH | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(5 years from now) | |
US10918635 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(6 years from now) | |
US11202752 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Apr, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 25, 2013 |
New Indication(I-636) | Mar 24, 2014 |
New Strength(NS) | Jul 15, 2014 |
Market Authorisation Date: 15 July, 2011
Treatment: Treatment of perianal warts; Treatment of actinic keratosis; Treatment of genital warts
Dosage: CREAM;TOPICAL